<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371660">
  <stage>Registered</stage>
  <submitdate>15/11/2016</submitdate>
  <approvaldate>8/12/2016</approvaldate>
  <actrnumber>ACTRN12616001692426</actrnumber>
  <trial_identification>
    <studytitle>Studies of Glucocorticoid Induced Hyperglycaemia - Part 1: effects of commonly prescribed Glucocorticoid (GC) regimens on blood sugar levels</studytitle>
    <scientifictitle>Continuous glucose monitoring to profile the effects of Glucocorticoid regimens on glycaemia.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Hyperglycaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Antenatal care</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To use continuous glucose monitoring (CGM) to profile the glycemic impact of commonly prescribed Glucocorticoid (GC) regimens. CGM will be applied for 3 days prior to the first dose of GC and continued for 3 days following GC administration at per the prescribed dose frequency (total duration 6 days)
</interventions>
    <comparator>Internal control; continuous glucose monitoring before and after administration of glucocorticoid
</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Peak interstitial fluid glucose induced by glucocorticoid administration, detected by CGM</outcome>
      <timepoint>Within 24 hours of each dose of glucocorticoid administered. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nadir glucose detected by CGM</outcome>
      <timepoint>Within 24 hours of each dose of glucocorticoid administered, detected by CGM</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>glycemic variability as assessed by the J-index calculated from CGM traces</outcome>
      <timepoint>24 hours post each dose of glucocorticoid administered</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of hyperglycaemia defined by the time spent with glucose greater than 7.8mmol/L during each 24 hour period post glucocorticoid administration</outcome>
      <timepoint>Within 24 hours of glucocorticoid administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of diabetes therapy as documented in the medical record</outcome>
      <timepoint>24 hours post glucocorticoid administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of hypoglycaemia defined by time spent with glucose &lt;4mmol/L during each 24 hour period post glucocorticoid administration</outcome>
      <timepoint>24 hours post glucocorticoid administration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with and without diabetes who are planned to have glucocorticoids for a medical indication.   </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects under the age of 18, subjects whose primary language is other than English, subjects with a cognitive impairment, an intellectual disability or a mental illness</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Descriptive statistics will be percentages for categorical data, mean +/- SD for normally distributed continuous data and median (interquartile range (IQR)) for non-normally distributed continuous or ordinal data. Paired and unpaired t-tests will be used to detect the differences in glycaemia and glycaemic variability between GC therapy and no GC therapy. The Wilcoxon rank test will be used to detect differences in ordinal data. Area under the glucose concentration-time curve will be measured using the trapezoidal rule. Results will be calculated using GraphPad Prism version 6.0a for Mac OS X, GraphPad Software (La Jolla California, USA). P values &lt;0.05 will be considered statistically significant. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>12/12/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/12/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <hospital>Sunshine Hospital - St Albans</hospital>
    <hospital>Footscray Hospital - Footscray</hospital>
    <postcode>3050 - Parkville</postcode>
    <postcode>3021 - St Albans</postcode>
    <postcode>3011 - Footscray</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Western Health Dept Diabetes and Endocrinology</primarysponsorname>
    <primarysponsoraddress>Dept Diabetes and Endocrinology
Furlong Rd
St Albans
VIC 3021</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Western Health Dept Diabetes and Endocrinology</fundingname>
      <fundingaddress>Sunshine Hospital
Furlong Rd
St Albans
VIC 3021</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Melbourne Hospital</fundingname>
      <fundingaddress>Dept Diabetes and Endocrinology
Grattan St
Parkville
VIC 3050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Melbourne Health</sponsorname>
      <sponsoraddress>Dept Diabetes and Endocrinology
Grattan St
Parkville
VIC 3050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To use continuous glucose monitoring (CGM) to profile the glycemic impact of commonly prescribed GC regimens. 

</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>MHHREC</ethicname>
      <ethicaddress>Grattan St 
Parkville
VIC 3050</ethicaddress>
      <ethicapprovaldate>5/09/2016</ethicapprovaldate>
      <hrec>HREC/16/MH/128 - 2016.117</hrec>
      <ethicsubmitdate>27/04/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Christopher Yates</name>
      <address>Dept Diabetes and Endocrinology
Royal Melbourne Hospital
Grattan St
Parkville
VIC 3050</address>
      <phone>+61 3 93427000</phone>
      <fax />
      <email>christopher.yates@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Yates</name>
      <address>Dept Diabetes and Endocrinology
Royal Melbourne Hospital
Grattan St
Parkville
VIC 3050</address>
      <phone>+61 3 93427000</phone>
      <fax />
      <email>christopher.yates@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Yates</name>
      <address>Dept Diabetes and Endocrinology
Royal Melbourne Hospital
Grattan St
Parkville
VIC 3050
</address>
      <phone>+61 3 93427000</phone>
      <fax />
      <email>christopher.yates@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Yates</name>
      <address>Dept Diabetes and Endocrinology
Royal Melbourne Hospital
Grattan St
Parkville
VIC 3050</address>
      <phone>+61 3 93427000</phone>
      <fax />
      <email>christopher.yates@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>